Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Bone health management
6 evidence topics · 4 sources
Consensus guideline: fracture risk, densitometry, calcium, and vitamin D
“There is higher risk of fracture due to immobility and use of anticonvulsants. If fracture occurs, consider bone density (DEXA) scan and referral to endocrine specialist (in addition to aggressive screen of calcium, vitamin D intake and 25-OH vitamin D levels).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ensure supplemental vitamin D intake: 600–1000 IU or more daily. Target serum levels of 25-OH-vitamin D greater than 30–40 ng/mL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With age, concern for low bone mineral mass coupled with long-term use of particular anticonvulsants raises the risks for osteoporosis and bone fractures” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bone health guideline: assessment and first-line interventions
“Agreement was reached on 39 statements which were formulated from 41 statements and 11 questions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A baseline densitometry assessment should be performed with accommodations made for size, with the frequency of surveillance determined according to individual risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing physical activity and initiating calcium and vitamin D supplementation when low are the first approaches to optimizing bone health in Rett syndrome. If individuals with Rett syndrome meet the ISCD criterion for osteoporosis in children, the use of bisphosphonates is recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bone health guideline: non-pharmacological and pharmacological statements with panel agreement
Bone health guideline: limited evidence for bisphosphonates
“Whilst the group agreed that bisphosphonate therapy may be indicated, several panel members did make note of the lack of evidence for efficacy and safety of bisphosphonate use in RTT and that its mechanism of action may be different from disorders such as osteogenesis imperfecta in which its use is frequent” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zoledronate: retrospective national center cohort
“Nine patients (23%) received zoledronate, for a mean 2 years. The mean age at zoledronate initiation was 9.7 ± 2.3 years. Four completed two DXA scans (pre- and post-treatment); the mean BMD Z-score improved from −2.2 ± 0.9 to −1.4 ± 0.9 after treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Poor L1–4 BMD Z-scores were associated with poor mobility scores (p = 0.05) and valproate treatment (p = 0.016).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zoledronic acid: annual infusion in children with cerebral palsy and Rett syndrome
“27 children under 18 years (19 with cerebral palsy and 8 girls with Rett syndrome confirmed by MCEP2 mutation) were treated with an annual injection of 0.1 mg/kg (max 4 mg) of ZA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No fractures have been observed in our cohort since the first infusion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Side effects (flu-like syndrome and hypocalcemia) were more common in younger patients and after the first infusion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote